ARKG vs XBI: Which Is the Better Pick in 2026?

Overview

ARKG and XBI both provide exposure to the biotechnology and genomics sector, but they pursue fundamentally different approaches. ARKG is an actively managed fund focused on genomic innovation—companies working in gene editing, CRISPR, and molecular diagnostics—while XBI tracks the S&P Biotechnology Select Industry Index using equal-weight methodology. The two funds overlap in some holdings but target different subsegments and operate under different management philosophies.

How they differ

The clearest distinction is strategy: ARKG pursues active stock-picking within genomics and gene therapy, while XBI follows a rules-based equal-weight index of a broader biotech universe. That active vs. passive split translates directly to fees—ARKG's expense ratio is 0.75% versus XBI's 0.35%—and to market sensitivity. ARKG carries a beta of 2.37, meaning it amplifies broad market moves by more than twice, whereas XBI's beta of 1.12 moves much closer to the market itself. AUM also differs substantially: XBI is a larger, more established fund with $10.4B compared to ARKG's $1.93B, and XBI has been running since 01/31/2006 while ARKG launched 10/31/2014.

Who each is best for

ARKG: Fits investors with higher risk tolerance seeking concentrated exposure to genomic innovation and gene-editing breakthroughs, willing to accept volatility and the possibility of significant drawdowns in exchange for upside if transformative therapies reach commercialization.

XBI: Designed for investors seeking broad-based biotech exposure with lower volatility and a modest income component, preferring a diversified, equal-weight approach across established and emerging biotech firms without the active-management fee or outsized beta.

Key risks to know

• High beta and amplified drawdowns. ARKG's 2.37 beta means it typically falls nearly 2.4 times faster than the broad market during corrections. During biotech sector selloffs, this amplification can result in steep NAV declines.

• Concentration in early-stage and loss-making companies. ARKG's focus on genomics and gene therapy means many holdings may not yet generate revenue. Clinical trial failures or regulatory setbacks at key portfolio companies can produce large, idiosyncratic losses.

• Equal-weight rebalancing drag. XBI's equal-weight methodology forces periodic rebalancing into smaller holdings and away from outperformers, which can underperform a market-cap-weighted approach in sustained uptrends and generate higher turnover costs.

• Sector cyclicality and FDA approval risk. Both funds are sensitive to sentiment swings around biotech drug approval timelines, patent expirations, and regulatory policy changes affecting gene therapy and diagnostics pricing and reimbursement.

• Overlap in holdings and correlated drawdowns. While ARKG and XBI target different segments, both are deeply exposed to biotech sector movements. A broad pullback in biotech valuations affects both funds similarly, limiting diversification benefit if held together.

Bottom line

If you want upside from cutting-edge genomic breakthroughs and can tolerate major swings, ARKG's active, concentrated bet on gene editing and molecular diagnostics offers a different risk-reward profile. If you prefer diversified biotech exposure at a lower cost and volatility, with a touch of income, XBI's broad equal-weight index approach keeps you exposed to the sector with simpler mechanics and less single-company risk. Past performance does not predict future results.